Insulin Potentiation Therapy in the Treatment of Malignant Neoplastic Diseases: A Three Year StudyChristo Damyanov*, Gherasimova DM, Avramov LA and Masley IK
Medical Center “Integrative Medicine,” Sofia, Bulgaria
- *Corresponding Author:
- Christo Damyanov, MD, PhD
bl.330 “Delijska vodenica”
“Drujba 2”, Medical Center “Integrative Medicine”
1582 Sofia, Bulgaria
Tel: +359 2 442 46 87; +359 2 442 47 31
Fax: +359 886 10 35 96
E-mail: [email protected]
Received date: April 04, 2012; Accepted date: April 23, 2012; Published date: April 25, 2012
Citation: Damyanov C, Gherasimova DM, Avramov LA, Masley IK (2012) Insulin Potentiation Therapy in the Treatment of Malignant Neoplastic Diseases: A Three Year Study. J Cancer Sci Ther 4: 088-091. doi:10.4172/1948-5956.1000117
Copyright: © 2012 Damyanov C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Problem Statement: Even after decades of scientific research, the application of chemotherapy in the management of neoplastic disease still presents numerous difficulties. Significant, amongst potential complications are numerous toxicity related side effects and the potential for chemoresistance. Despite the widespread tendency to include a variety of new chemotherapeutics in different combinations, progress in this area has proven slow going and unsatisfactory due to the aforementioned factors. 3
Approach: Seeking a new approach, we introduced the method of Insulin Potentiation Therapy (IPT) in our practice. The theoretical basis and the gathered experimental data on insulin’s mode of action, as well as its application in practice, show that IPT is a promising method with low toxicity. Moreover, it facilitates a selectively physiological approach to the management of neoplastic disease using chemotherapy.
In this report we present the results of our three-year experience applying Insulin Potentiation Targeted Therapy Low Dose (IPTLD) in the treatment of 196 patients diagnosed with a variety of neoplastic diseases
Results: Our results showed that patients tolerated IPTLD without difficulties, without serious side effects. Our laboratory tests demonstrated that the dose related toxicity of chemotherapeutics could be largely mitigated when applied in conjunction with insulin, at a fractionated dose in accordance with a dose dense regimen. Upon follow-up, eighty five of 106 patients (80%) with advanced metastatic disease reported a subjectively significant improvement in their quality of life.
Conclusions: Future extended experimental data and clinical trials would contribute to a more complete understanding of the therapeutic potential of IPTLD.